Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.34 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | KAT7 | O95251 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19962898 | 0.90 | DRD2 (0.37) | GABRA2DRD2MELKKAT7KAT5 | |
| SCHEMBL19962964 | 0.89 | DRD2 (0.37) | GABRA2DRD2MELKCYP3A4CYP2C19 | |
| SCHEMBL19963011 | 0.88 | DRD2 (0.39) | GABRA2DRD2MELKKAT7KAT5 | |
| SCHEMBL19962958 | 0.87 | DRD2 (0.38) | GABRA2DRD2MELKKAT7KAT5 | |
| SCHEMBL19962966 | 0.85 | MELK (0.35) | GABRA2DRD2MELKKCNH2 | |
| SCHEMBL19962963 | 0.84 | GABRA2 (0.41) | GABRA2MELKALOX5APFEN1 | |
| SCHEMBL21130659 | 0.83 | GABRA2 (0.37) | GABRA2MELKALOX5APFEN1 | |
| SCHEMBL19962899 | 0.83 | BRD4 (0.33) | DRD2MELK | |
| SCHEMBL19962965 | 0.82 | GPR119 (0.32) | DRD2MELK | |
| SCHEMBL19962961 | 0.82 | GPR119 (0.32) | DRD2MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2020132700-A1 | METHODS OF USING INHIBITORS OF SREBP IN COMBINATION WITH NICLOSAMIDE AND ANALOGS THEREOF | Fgh Biotech Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018049080-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | GABRA2 3372/4885DRD2 4559/4885MELK 1854/4885 |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | GABRA2 3372/4885DRD2 4559/4885MELK 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.